Key Takeaways
Extended Takeaways
- The population pharmacokinetic model was built from 5,731 plasma paliperidone concentrations in 276 subjects and showed good agreement between simulated and observed 5th, 50th, and 95th percentiles, supporting the credibility of the exposure comparisons used for these off-label scenarios.
- With LY03010 351 mg Q4W in the deltoid, median Cavg,ss was 76.3 [42, 133] ng/mL versus 50.9 [25.8, 95.4] ng/mL with IS 234 mg Q4W, and exposure was comparable to IS 234 mg Q3W at 67.3 [33.9, 124] ng/mL, making this regimen pharmacokinetically closer to an intensified PP1M schedule than to standard monthly dosing.
- If a longer interval is desired without materially changing overall exposure from IS 234 mg Q4W, LY03010 351 mg Q6W produced closely matched steady-state values: Cmax,ss 67.9 [41.3, 108] ng/mL, Ctrough,ss 34.5 [11.9, 74.2] ng/mL, and Cavg,ss 51.7 [28.8, 89.5] ng/mL versus 66.3 [37.3, 113], 39 [13.7, 84.7], and 50.9 [25.8, 95.4] ng/mL with IS 234 mg Q4W.
- For LY03010 351 mg Q8W, clinicians should expect mixed equivalence rather than a simple monthly-dose match: Cmax,ss and Cavg,ss were between IS 234 mg Q4W and 156 mg Q4W, while Ctrough,ss was 20.6 [5.25, 49.9] ng/mL, comparable to IS 117 mg Q4W at 19.6 [6.85, 42.5] ng/mL.
- Injection site did not meaningfully alter maintenance exposure in these simulations, as deltoid and gluteal administration of LY03010 351 mg produced similar steady-state paliperidone levels across Q4W, Q6W, and Q8W regimens.
- Higher-exposure strategies may increase the proportion of patients crossing the laboratory alert level of 120 ng/mL: approximately 18.5% with LY03010 351 mg Q4W deltoid and 16.2% with gluteal versus 12.6% with IS 234 mg Q3W deltoid, reinforcing the need to monitor for extrapyramidal symptoms and prolactin-related adverse effects when using intensified paliperidone palmitate dosing.
